Displaying 49 - 60 of 60
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Viral Hepatitis
2

GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk:  NASH – the metabolic disease of the liver - Digital ILC 2020

View
Displaying 49 - 60 of 60